A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Baumann, K. H.; du Bois, A.; Meier, W.; Rau, J.; Wimberger, P.; Sehouli, J.; Kurzeder, C.; Hilpert, F.; Hasenburg, A.; Canzler, U.; Hanker, L. C.; Hillemanns, P.; Richter, B.; Wollschlaeger, K.; Dewitz, T.; Bauerschlag, D.; Wagner, U.

Erstveröffentlichung

2012

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Baumann, K. H.

du Bois, A.

Meier, W.

Rau, J.

Wimberger, P.

et al.

Institutions

UKU. Klinik für Frauenheilkunde und Geburtshilfe

Published in

Annals of Oncology ; 23 (2012), 9. - S. 2265-2271. - ISSN 0923-7534. - eISSN 1569-8041

Link to publication

https://dx.doi.org/10.1093/annonc/mds003

Keywords

angiogenesis inhibitor; ovarian cancer; platinum resistant; sunitinib; RECURRENT EPITHELIAL OVARIAN; ENDOTHELIAL GROWTH-FACTOR; ANTITUMOR-ACTIVITY; INTERGROUP TRIAL; CARCINOMA; PACLITAXEL; CARBOPLATIN; GUIDELINES; CISPLATIN

Dewey Decimal Group

DDC 610 / Medicine & health

Metadata

Show full item record